Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/1/2020
SIETES contiene 92882 citas

 
 
 1 a 20 de 290 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]
2. Cita con resumen
Aronson JK, Ferner RE. How similar are biosimilars?. BMJ 2016;353:i2721. [Ref.ID 100310]
4.Enlace a cita original Cita con resumen
Larráyoz B. Medicamentos biosimilares. Concepto, regulación y controversias en su utilización. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-11. [Ref.ID 99826]
5. Cita con resumen
Robles NR, Macías JF, Herrera J. Uso de agentes estimuladores de la reitropoyesis en pacientes con insuficiencia cardíaca congestiva. Med Clin (Barc) 2014;142:215-8. [Ref.ID 97268]
6. Cita con resumen
Coyne DW. Anemia in chronic kidney disease: treating the numbers, not the patients. JAMA Intern Med 2014;174:708-9. [Ref.ID 97192]
7. Cita con resumen
Kansagara D, Dyer E, Englander H, Fu R, Freeman M. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med 2013;159:746-57. [Ref.ID 96652]
8. Cita con resumen
Avorn J. Healing the overwhelmed physician. N Y Times (Print) 2013:11 de junio. [Ref.ID 95635]
9.Enlace a cita original
Heuberger JAAC, Tervaert JMC, Schepers FML, Vliegenthart ADB, Rotmans JI, Daniels JMA, Burggraaf J, Cohen AF. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol 2013;75:1406-21. [Ref.ID 95567]
10. Cita con resumen
Anónimo. What are biosimilars and are they important?. Drug Ther Bull 2013;51:57-60. [Ref.ID 95385]
11. Cita con resumen
Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2. [Ref.ID 95286]
12.Tiene citas relacionadas
Drüeke TB. Anemia treatment in patients with chronic kidney disease. N Engl J Med 2013;368:387-9. [Ref.ID 94809]
13.Tiene citas relacionadas Cita con resumen
Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S, PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32. [Ref.ID 94806]
14.Tiene citas relacionadas Cita con resumen
Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duilege A-M, Besarab A, for the EMERALD Study Groups. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19. [Ref.ID 94805]
15. Cita con resumen
Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Pharmacoepidemiol Drug Saf 2012;21:857-64. [Ref.ID 93529]
17. Cita con resumen
Yuki N, Hartung H-P. Medical progress: Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304. [Ref.ID 93212]
18. Cita con resumen
Anónimo. Peginesatide (Omontys) for anemia in chronic kidney disease. Med Lett Drugs Ther 2012;54:45-6. [Ref.ID 93204]
19. Cita con resumen
Epstein K. Full results on risk of epoetin emerge 14 years after study. BMJ 2012;344:2. [Ref.ID 92999]
20.Tiene citas relacionadas Cita con resumen
Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB, ESA Clinic Study Group. Impact of pharmacist-managed erythropoiesis - Stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012;60:371-9. [Ref.ID 92943]
Seleccionar todas
 
 1 a 20 de 290 siguiente >>